During the past decade, Ospedale Centrale di Bolzano conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 4 clinical trials were completed, i.e. on average, 19% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 4 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ospedale Centrale di Bolzano" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 4 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 3 trials sponsored, "Mario Negri Institute for Pharmacological Research" with 2 trials sponsored, "A.O. Ospedale Papa Giovanni XXIII" with 1 trials sponsored and "Associazione Angela Serra per la ricerca sul cancro" with 1 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ospedale Centrale di Bolzano" #1 collaborator was "Gruppo Oncologico Italiano di Ricerca Clinica" with 2 trials as a collaborator, "Alexion Pharma Italy s.r.l." with 1 trials as a collaborator, "Azienda Ospedaliera San Gerardo di Monza" with 1 trials as a collaborator, "Azienda Ospedaliera di Bolzano" with 1 trials as a collaborator and "Azienda Ospedaliero-Universitaria di Modena" with 1 trials as a collaborator. Other collaborators include 14 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Ospedale Centrale di Bolzano" are "Leukemia" (2 trials), "Lymphoma, T-Cell, Peripheral" (2 trials), "Syncope" (2 trials), "Acute Lymphoid Leukemia" (1 trials) and "Acute Myocardial Infarction" (1 trials). Many other conditions were trialed in "Ospedale Centrale di Bolzano" in a lesser frequency.

Most popular intervention types in "Ospedale Centrale di Bolzano" are "Drug" (23 trials), "Procedure" (5 trials), "Biological" (1 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "5-Fluorouracil" (1 trials), "Adalimumab" (1 trials), "Allogeneic SCT or Autologous SCT" (1 trials), "Bendamustine + Rituximab" (1 trials) and "CHOP" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ospedale Centrale di Bolzano" are 32 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Ospedale Centrale di Bolzano". undefined are not yet recruiting, 3 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Ospedale Centrale di Bolzano, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Ospedale Centrale di Bolzano, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 5 trials that are defined as “Not Applicable".